Summit Announces a Client Partnership with Opiant

Opiant Pharmaceuticals, Inc. has entered into a Project Scope Agreement, pursuant to a Master Services Agreement with Summit Biosciences, to support the development and manufacture of a nasal spray device for opioid overdose, with the ability to expand to additional programs in the future. Summit will develop and produce certain pre-filled nasal spray products using a device previously evaluated as part of other FDA-approved nasal spray products.

About Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc., the company that developed NARCANĀ® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.

For more information visit: